182 related articles for article (PubMed ID: 28786276)
1. [PRECLINICAL RHEUMATOID ARTHRITIS].
Elalouf O; Elkayam O
Harefuah; 2017 Jul; 156(7):451-454. PubMed ID: 28786276
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid arthritis.
Scott DL; Wolfe F; Huizinga TW
Lancet; 2010 Sep; 376(9746):1094-108. PubMed ID: 20870100
[TBL] [Abstract][Full Text] [Related]
3. Preclinical rheumatoid arthritis and rheumatoid arthritis prevention.
Greenblatt HK; Kim HA; Bettner LF; Deane KD
Curr Opin Rheumatol; 2020 May; 32(3):289-296. PubMed ID: 32205569
[TBL] [Abstract][Full Text] [Related]
4. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Rheumatoid Arthritis and Rheumatoid Arthritis Prevention.
Deane KD
Curr Rheumatol Rep; 2018 Jun; 20(8):50. PubMed ID: 29946747
[TBL] [Abstract][Full Text] [Related]
6. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
[TBL] [Abstract][Full Text] [Related]
7. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
8. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
[TBL] [Abstract][Full Text] [Related]
9. IgM-rheumatoid factor and anti-cyclic citrullinated peptide decrease by 50% during intensive treatment in early rheumatoid arthritis.
van Tuyl LH; Lems WF; Kerstens PJ; Voskuyl AE; Dijkmans BA; Boers M
Ann Rheum Dis; 2009 Oct; 68(10):1652-3. PubMed ID: 19748920
[No Abstract] [Full Text] [Related]
10. Preclinical rheumatoid arthritis (autoantibodies): an updated review.
Deane KD
Curr Rheumatol Rep; 2014 May; 16(5):419. PubMed ID: 24643396
[TBL] [Abstract][Full Text] [Related]
11. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
[TBL] [Abstract][Full Text] [Related]
12. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
[TBL] [Abstract][Full Text] [Related]
13. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
[TBL] [Abstract][Full Text] [Related]
14. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF
Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
[TBL] [Abstract][Full Text] [Related]
15. Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
Ally MM; Hodkinson B; Meyer PW; Musenge E; Tintinger GR; Tikly M; Anderson R
BMC Musculoskelet Disord; 2015 May; 16():130. PubMed ID: 26021985
[TBL] [Abstract][Full Text] [Related]
16. Rheumatoid arthritis.
Klareskog L; Catrina AI; Paget S
Lancet; 2009 Feb; 373(9664):659-72. PubMed ID: 19157532
[TBL] [Abstract][Full Text] [Related]
17. B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens.
Cambridge G; Leandro MJ; Lahey LJ; Fairhead T; Robinson WH; Sokolove J
J Autoimmun; 2016 Jun; 70():22-30. PubMed ID: 27055777
[TBL] [Abstract][Full Text] [Related]
18. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study.
Gerlag DM; Safy M; Maijer KI; Tang MW; Tas SW; Starmans-Kool MJF; van Tubergen A; Janssen M; de Hair M; Hansson M; de Vries N; Zwinderman AH; Tak PP
Ann Rheum Dis; 2019 Feb; 78(2):179-185. PubMed ID: 30504445
[TBL] [Abstract][Full Text] [Related]
19. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment.
Di Muzio G; Perricone C; Ballanti E; Kroegler B; Greco E; Novelli L; Conigliaro P; Cipriani P; Giacomelli R; Perricone R
Int J Immunopathol Pharmacol; 2011; 24(2):357-66. PubMed ID: 21658310
[TBL] [Abstract][Full Text] [Related]
20. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
